HomeAI · summaries
Storia in 5 fonti
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk, Celcuity Inc.) plus fulvestrant, with or without palbociclib (Ibrance, Pfizer), was approved for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression during or after
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
PAM Inhibitor Approved for HR-Positive Breast Cancer
Gedatolisib is approved in combination with fulvestrant, with or without palbociclib
- ·
endpoints.news
Celcuity wins approval for breast cancer drug Revtorpyk
Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.
